SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-190074
Filing Date
2023-07-20
Accepted
2023-07-20 06:55:51
Documents
14
Period of Report
2023-07-20
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d485991d8k.htm   iXBRL 8-K 26283
2 EX-99.1 d485991dex991.htm EX-99.1 7087
6 GRAPHIC g485991g0720064127052.jpg GRAPHIC 7322
  Complete submission text file 0001193125-23-190074.txt   172579

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA elym-20230720.xsd EX-101.SCH 2839
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE elym-20230720_lab.xml EX-101.LAB 18738
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE elym-20230720_pre.xml EX-101.PRE 11700
8 EXTRACTED XBRL INSTANCE DOCUMENT d485991d8k_htm.xml XML 3483
Mailing Address 23515 NE NOVELTY HILL ROAD SUITE B221 #125 REDMOND WA 98053
Business Address 23515 NE NOVELTY HILL ROAD SUITE B221 #125 REDMOND WA 98053 877-354-3689
Eliem Therapeutics, Inc. (Filer) CIK: 0001768446 (see all company filings)

IRS No.: 832273741 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40708 | Film No.: 231098050
SIC: 2834 Pharmaceutical Preparations